AbbVie Says 55% Of Crohn’s Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson

All NewsMarch 2, 2026

AbbVie says 55% of Crohn’s patients reached remission in a late-stage study, boosting Skyrizi’s outlook amid market competition.

Latest Ratings for ABBV

DateFirmActionFromTo Feb 2022UBSDowngradesBuyNeutral Feb 2022MizuhoMaintainsBuy Feb 2022BarclaysMaintainsEqual-Weight

View More Analyst Ratings for ABBV

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent